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ABSTRACT 
 
 
The Encapsulation of Rat Aortic Smooth Muscle Cells Within Porous Scaffold 
 (April 2008) 
 
 
Alexandra Iacob 
Biomedical Engineering 
Texas A&M University 
 
Research Advisor: Dr. Mariah S. Hahn 
Department of Chemical Engineering 
 
Growing rat aortic smooth muscle cells (RASMC) in vitro has posed numerous 
difficulties in the past. Smooth muscle cells are known to need a three-dimensional (3-D) 
structure, neighboring cells, space to allow for elongation and media to encourage normal 
behavior. Current technology in polymers presents a potential means to create a 3-D 
porous environment that mimics the natural habitat for RASMC. Through this experiment 
various methods have been employed to produce the optimal structure for the cells. Cells 
are encapsulated in rapidly degrading polyethylene glycol (PEG) bead-shaped gels. These 
beads are then encapsulated in a cross-linked PEG rectangular scaffold. In time, the beads 
degrade while the cells remain intact. In essence, this allows for the creation of open 
pores in which the cells remain. The cells then have the chance to elongate and assume 
natural shape and behavior. The method proposed has shown successfully that upon the 
beads’ degradation, the cells remain intact within the PEG hydrogel scaffold. 
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CHAPTER I 
INTRODUCTION 
 
 
Organ and tissue failure due to accidents or disease are an increasing concern in the 
medical field.8 The number of needed transplants far outnumber the available donors.7 
One method to overcome this need is to create artificial organs or tissues. This study 
focuses particularly on blood vessels. The first tissue engineered artificial blood vessel 
was made in 1984 by mixing cultured endothelial cells, smooth muscle cells and 
fibroblasts integrated with a Dacron mesh.3 The underlying paradigm of tissue 
engineering is that cells must be placed in a scaffold, or three dimensional (3D) context, 
that mimics the cells’ native environment to encourage normal behavior, i.e. cell-cell 
interconnections, communications, etc.  
 
Hydrogels are a group of materials that seem to have strong potential as tissue 
engineering scaffolds.7 Hydrogels based on polymers are advantageous because they are 
similar to the natural extracellular matrix (ECM) in that they are well hydrated 3D 
“networks that provide a place to for cells to adhere, proliferate and differentiate”.2 
Poly(ethylene glycol) (PEG) based hydrogels are one type of synthetic scaffolds 
frequently used in tissue engineering and drug delivery applications. 6  
This thesis follows the style of Annals of Biomedical Engineering.  
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PEG has interested many due to its biocompability, hydrophilicity, high permeability, 
controllable bioactivity, and resistance to protein adsorption and cell adhesion.11, 12 The 
plain PEG chains are modified via acrylation to promote cross-linking of the chains, 
allowing for a structured gel. Unfortunately, one of the drawbacks of this hydrogel is its 
dense mesh structure of polymer chains that immobilize the “seeded” cells, preventing 
normal cell elongation and interconnection.5 Upon placing cells within simple PEG 
scaffolds, the cells maintain a spherical shape since they are unable to break the dense 
structure and assume natural shape2. One approach researchers have developed to correct 
for this drawback of PEG hydrogels was to create a solid but hydrolytically degradable 
polymer mold, polymerized PEG around this mold, and then dissolve away the mold by 
the addition of sodium hydroxide. 4 This created a network of large pores within the 
scaffold. Neural progenitor cells were then implanted in the scaffold. However, the cells 
were not evenly distributed and were mostly concentrated on the surface.  
 
A separate study attempted to introduce pores within PEG hydrogels by polymerizing the 
PEG macromers around polystyrene beads. The polystyrene beads were then dissolved 
by the addition of an organic solvent, leaving behind an open porous structure.1 
However, the use of a harsh organic solvent is undesirable in tissue engineering 
applications, and cell seeded in the resulting scaffolds are prone to uneven distribution. 
To overcome the immobilizing deficit of encapsulating cells directly into the PEG 
hydrogel and the uneven distribution of cells associated with other methods of creating 
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macropores within PEG hydrogels, harvested rat aortic smooth muscle cells (RAMSC) 
will first be encapsulated within carrier beads composed of a rapidly degradable 
modification of PEG.  
 
Many polymers also have the possibility to be chemically altered, lowering their half-life 
drastically by the addition of lactides or glycolides at the end of the chains; 10 PEG is one 
such.9 In this case, this secondary PEG is altered by adding glycolides or lactides to the 
end of each polymer chain prior to acrylation. The glycolide/lactide segments are 
hydrolytically cleavable and thus the hydrogel crosslinks degrade as these segments are 
cleaved. Degradable PEG bead “carriers” are then encapsulated within a plain PEG 
hydrogel. As the beads degrade, the cells will remain, as will an open-pore structure. The 
open pores should allow the cells to elongate and assume a more natural morphology. 
Figures 1 and 2 below briefly illustrate these few steps. 
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FIGURE 1. RASMC (red spheres) encapsulated in the rapidly degradable PEG beads (blue) within a PEG hydrogel 
(yellow). 
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FIGURE 2. RASMC (red structures) elongated in previous beads’ space within a PEG hydrogel (yellow). 
 
 
 
This work investigates the method of generating such an optimal scaffold to encourage 
normal behavior.  
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CHAPTER II 
METHODS 
 
 
The methods for bead fabrication and encapsulation can be broken down in several main 
steps: addition of lactides or glycolides to PEG, diacrylation of PEG, forming the 
PEGDA beads, observating degradation of PEGDA beads, encapsulating the RASMC in 
the PEGDA beads, encapsulating the beads with cells in the gel to create the final 
scaffold, and observing the degradation of the PEGDA beads within the scaffold. 
 
Materials and equipment 
All PEG used was purchased from Fluka, argon gas from Botco, stannous octoate from 
Pfaltz&Bauer, Inc, dichloromethane and acryoyl chloride from Sigma, triethylamine 
from J.T. Baeker, MgSO4 from Acros, K2CO3 from Fisher Scientific, and HEPES 
buffered saline (HBS) from HyClone.  Acetophenone used in this experiment was made 
with 1 ml 1-vinyl-2-pyrrolidinone 99+% (purchased from Sigma-Aldrich) and 300mg 2-
2-dimethoxy-2-phenyl acetophenone (purchased from TCI America). A Mercury 300 
MHz NMR with field strength of 300 MHz was used along with an Ultra-Violet Products 
Inc. UV lamp with a wavelength of 365 nm and a Fisher-Scientific Micron Microscope 
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with the lens of 160/1.5. Fluorescent detection was carried out using 488/532 
excitation/emission filters and an Axiovert A200 microscope.  
 
Adding lactides or glycolides to PEG 
To begin this experiment I first created the PEG glycolide. The following procedure is 
very sensitive to moisture, so it was conducted in a very dry and inert environment. To 
ensure this, all glassware was heated to 150 oC overnight and the system was evacuated 
with argon between each of the following steps. The purpose is to take the regular PEG 
chain and add an opened lactide or glycolide ring to both ends of the chain with the help 
of stannous octoate as a catalyst. The reaction is depicted below in Figure 3.  
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FIGURE 3. Addition of lactides to PEG followed by acrylation to create degradable PEGDA. 
 
I started with PEG (MW 3500, Fluka) and placed it in a 250 ml round bottom flask. The 
flask was purged with argon in between all steps. I then added D, L – lactides or 
glycolides (depending on which PEG I wanted to make) in a 4:1 molar ratio of 
lactides/glycolides to PEG. Stannous octoate was then added in a 1:200 mass ratio to 
PEG. The solution was heated to 140 oC in an oil bath and the reaction was allowed to 
proceed for 4 h. The product of the reaction was purified in order to remove the catalyst, 
stannous octoate, and the unreacted lactide/glycolide by dissolving in methylene chloride 
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and precipitating with diethyl ether. This new PEG was analyzed using 13C NMR to 
confirm lactide conjugation. The confirmation is achieved by a characteristic peak on the 
free methyl group and the peaks of the lactides/glycolide and via the quantative analysis 
by comparing with the areas of the peaks of the methyl protons.  
 
Diacrylation of PEG  
The PEG was placed in a 250 ml round bottom flask and dissolved in dichloromethane. 
The flask was then flushed with argon. Afterwards, acryoyl chloride and triethylamine 
were added in a 2:1 molar ratio to PEG-lactide and a 1:1 molar ratio to PEG-lactide, 
respectively.  The reaction took place overnight, for at least 12 h. The diacrylated PEG 
dilactide (PEGDA) was purified by the addition of 2M K2CO3 followed by phase 
separation. This removes HCl. The organic phase was retrieved and dried with anhydrous 
MgSO4. The product was precipitated in diethyl ether. I then dried the product 
thoroughly overnight and crushed it to fine powder. The powder was stored at -20 oC 
until ready to use.  
 
Forming PEGDA beads 
The PEGDA powder previously prepared was combined in a 3:10 mass ratio in a glass 
tube with HEPES buffered saline (HBS).  The mixture was vortexed until homogeneity 
was obtained, for approximately 1 min, between each of the following steps. Then 
10 
 
acetophenone was added in a 1:50 mass ratio to the mixture, without exposing the 
container to any light source. This step allowed the polymer to bind to neighboring 
chains. Afterwards silicone oil was added in a 10:3 mass ratio. This allowed the beads to 
form and be completely isolated via the oil. At this point, the container was exposed to 
UV lamp for 10 min, allowing the beads to harden. To remove the oil, phosphate 
buffered solution (PBS) was added, the solution was mixed and then centrifuged at room 
temperature, 800g speed. The supernatant containing oil and PBS was discarded and this 
washing procedure was repeated twice to remove residual oil.  
 
Observing degradation of PEGDA beads 
The PEGDA beads previously prepared were simply placed in a petri dish with HBS. 
The beads were checked on a regular basis, at least once every 8 h. Degradation was 
characterized by porous surface on beads and chunks missing within the beads. When the 
beads had completely degraded, a film of loose milky particles floating on top was 
observed.  
  
Encapsulating the RASMC in the PEGDA beads 
RASMC in culture were collected and counted using a hemacytometer. The degradable 
PEGDA powder previously prepared was combined in a 3:10 mass ratio in a glass vial 
with HBS.  The mixture was vortexed until homogeneity was obtained (for 
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approximately 1 min) between each of the following steps. The cells were added in a 
5.83 million cells per each 1ml of bead volume ratio to the PEGDA solution volume. 
Then acetophenone was added in a 1:50 mass ratio to the mixture, without exposing the 
container to any light source. This step allowed the polymer to bind to neighboring 
chains. Afterwards silicone oil was added in a 10:3 mass ratio. This allowed the beads to 
form and be completely isolated via the oil. At this point, the container was exposed to 
UV lamp for 10 min, allowing the beads to harden. To remove the oil, PBS was added, 
the solution was mixed and then centrifuged at room temperature at 800g speed three 
times, for 6 min, 12 min, and 12 min, respectively. After each spin, the top oil layer and 
PBS were removed from the tube, until hardly any oil remained.  
 
Forming the scaffold 
PEGDA (MW 6k, 2 acrylations, no degradable segments) was combined in a 3:10 mass 
ratio in a glass tube with HBS.  The mixture was vortexed until homogeneity was 
obtained between each of the following steps. Acetophenone was added in a 1:100 mass 
ratio to the mixture, without exposing the container to any light source. This step allowed 
the polymer to bind to neighboring chains. Afterwards the beads were added in a 19:20 
mass ratio to the PEGDA solution. The solution with the beads was poured in a scaffold 
mold, created out of glass plates with 1.1 mm spacers, which allowed a flat 3D 
rectangular scaffold to form. At this point, the mold was exposed to UV lamp for 
1min/side for a total of 2 min, allowing for the solution to harden. The scaffold was then 
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removed and analyzed with a microscope to confirm encapsulation of beads. The 
scaffold was then transferred to either PBS or cell culture media and maintained at 37 
°C/5% CO2. 
 
Observing the degradation of the PEGDA beads within the scaffold 
The above steps for the encapsulation of the cells in the beads and encapsulating the 
beads into the scaffold were followed with the single exception that eosin-Y (a 
fluorophor) was added along with acetophenone in a 1:1000 ratio to the bead volume. 
The rest of the steps were followed exactly. To view the degradation of the beads within 
the scaffold, the scaffold was exposed to the fluorescent setting of the microscope and 
eosin-Y was visible in the beads that had not degraded yet.  
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CHAPTER III 
RESULTS 
 
 
The first procedure was creating various degradable PEGDAs to test their ability to form 
beads and their degradation rate. The table below lists the degradable PEGDAs created 
with the following code: PEG MW, number of glycolides or lactides added, and the 
number of acrylations performed. The table also specifies whether beads were formed or 
not, and if so, how many days it took for the beads to degrade.  
 
TABLE 1. PEGDAs Tested for Beads. 
PEGDA 3.4k 4 glyc  
6 acryl  
6k 8 glyc  
2 acryl 
10k 8 glyc 
1 acryl 
6k 2 lact 
1 acryl 
Beads Formed Yes Yes Yes No 
Days Necessary 
for Degradation 
5 7+ 3 n/a 
 
Degradation was characterized by observing the status of the beads formed. Degradation 
was defined as chunks of beads missing, porous sites visible in the beads, and in the final 
stage loose milky appearance of beads reminisces. Figure 4 depicts the first signs of 
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degradation seen only after one day. The complete degradation of the beads can be seen 
after three days in figure 5.  
 
 
FIGURE 4. 10k 8 glyc 1 acryl PEGDA beads degradation example at one day after formation. 
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FIGURE 5. 10k 8 glyc 1 acryl PEGDA beads degradation example at three days after formation. 
 
To verify that the PEGDA that would be used for the actual scaffold and not for the 
beads would not degrade considerably during the time of the experiment, we 
characterized its degradation in 3D rectangular scaffold form over two weeks. The 
following figures 6 and 7 illustrate how degradation was established.  
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FIGURE 6. 6k 2 acryls PEGDA scaffold at formation. 
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FIGURE 7. 6k 2 acryls PEGDA scaffold at five days after formation.  
 
As seen in figure 5 and 6 no degradation was observed in 3.4K 2 acryl PEGDA: the edge 
of the scaffold remained intact and had no porosity appear due to degradation. This 
justifies its use in encapsulating the degradable beads. 
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FIGURE 8. 3.4K 2 acryls PEGDA scaffold at thirteen days after formation. 
 
After establishing which degradable PEGDA to use for the beads and that the chosen 
PEGDA for the scaffold is suitable since it has practically no degradation, the cells were 
embedded via the methods described in the previous chapter. The images portrayed in 
figures 8, 9, and 10 were seen through the Micron microscope. Figure 9 depicts the 
scaffold two days after encapsulation. At this time, the outline of the beads can still be 
seen (see the arrows) indicating no significant degradation yet (the cells appear as the 
darker red areas).  
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FIGURE 9.  Micron microscope view of cells encapsulated within PEGDA 10k 8 glyc 1 acryl beads in PEGDA 6k two 
days after encapsulation.  
 
Figures 10 and 11 show the degradation of the beads in time. Figure 10 depicts the 
scaffold after four days and some bead outlines can still be seen. However, some of the 
previously noted ones have faded, indicating degradation.  
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FIGURE 10. Micron microscope view of cells encapsulated within PEGDA 10k 8 glyc 1 acryl beads in PEGDA 6k four 
days after encapsulation.  
 
Figure 11 depicts the scaffold at seven days after encapsulation. At this point, barely any 
bead outlines can be seen. Hence, the beads have mostly degraded within the scaffold 
and the cells seem intact.  
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FIGURE 11. Micron microscope view of cells encapsulated within PEGDA 10k 8 glyc 1 acryl beads in PEGDA 6k seven 
days after encapsulation.  
  
To further verify the method, a fluorescence technique was used. The PEGDA of the 
beads had eosin-Y introduced at formation allowing it to appear bright green under 
fluorescent light. Figure 12 shows a scaffold with only beads embedded (no cells within) 
which were fluorescent. This image was taken 5 days after the encapsulation. The beads 
closer to the edge have clearly less fluorescence than the inner beads. This finding is very 
important since is suggests that even though the beads do degrade (see figure 9, 10, 11) 
the degraded PEDGA is limited in its ability to diffuse out of the now open pore site.  
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FIGURE 12. Fluorescent view of degrading beads within scaffold.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
 
The goal of this study was to find a method to encapsulate RASMC within a porous 
scaffold. The goal was successfully completed by first introducing the RASMC in 10k 8 
glyc 1 acryl PEGDA gel, forming beads of this gel, and encapsulating these beads within 
6k 2 acryl PEGDA to create the porous scaffold. The beads degraded within several days 
allowing more mobility for the cells. However, despite the porosity and hydrophilicity of 
the PEGDA scaffold, the degraded PEGDA did not leave the open pore sites.  
 
For future studies, the scaffold should be optimized. The first problem to address is to 
create a scaffold in which the degraded PEGDA is able to rapidly diffuse out of the open 
pore sites.  
 
A second problem to address is to find the optimal concentration of beads to scaffold and 
whether the bead size affects the cell behavior. This could be done by implememting 
various pore densities and pore sizes within the scaffold and then histologically 
analyzing the cells’ interconnections and behavior.  
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A third concept would be to move from the flat 3D scaffold to a tubular scaffold. 
Hopefully the cells would bend with the tubular structure and thus mimic a vascular 
vessel. Further investigation into the method presented in this study would answer the 
above questions. 
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